Skip to main content
SpringerLink
Log in

Botulinum Toxin Treatment of Movement Disorders

  • Chapter
Book cover Parkinson’s Disease and Movement Disorders

Part of the book series: Current Clinical Practice ((CCP))

  • 532 Accesses

General Overview

Botulinum toxins are the most deadly neurotoxins known and are produced by the anaerobic bacterium Clostridium botulinum. C. botulinum produces seven antigenically (immunologically) distinct neurotoxins: A, B, C1, D, E, F, and G. These neurotoxins block neuromuscular transmission, resulting in both skeletal and smooth muscle paralysis. Clinically, botulism can occur after ingestion of contaminated food or from a wound infection. Signs of botulism can include limb paralysis, facial weakness, ophthalmoplegia, dysarthria, dysphagia, dyspnea progressing to respiratory arrest, constipation progressing to ileus, and urinary retention.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Selected Reading

  • Brin MF, Blitzer A, Herman S, Stewart C. Oromandibular dystonia: treatment of 96 patients with botulinum toxin type A, in Therapy With Botulinum Toxin ( Jankovic J, Hallett M eds), Marcel Dekker, New York, 1994, pp. 429–435.

    Google Scholar 

  • Brin MF, Lew MF, Adler CH, Cornelia CL, Jankovic J, O’Brien C, Murray JJ, Wallace JD, Willmer-Holme A, Koller M. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 1999; 53: 1431–1438.

    Article  PubMed  CAS  Google Scholar 

  • Greene P. Controlled trials of botulinum toxin for cervical dystonia: a critical review, in Therapy With Botulinum Toxin ( Jankovic J, Hallett M eds), Marcel Dekker, New York, 1994, pp. 279–287.

    Google Scholar 

  • Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994; 9: 213–217.

    Article  PubMed  CAS  Google Scholar 

  • Jankovic J. Botulinum toxin in movement disorders. Curr Opin Neurol 1994; 7: 358–366. Jankovic J, Schwartz K. Botulinum toxin treatment of tremors. Neurology 1991; 41: 1185–1188.

    CAS  Google Scholar 

  • Price J, Farish S, Taylor H, O’Day J. Blepharospasm and hemifacial spasm. Randomized trial to determine the most appropriate location for botulinum toxin injections. Ophthalmology 1997; 104: 865–868. Pulmann SL, Greene P, Fahn S, Pedersen SF. Approach to the treatment of limb disorders with botulinum toxin A. Experience with 187 patients. Arch Neurol 1996; 53: 617–624.

    Article  Google Scholar 

  • Schantz EJ, Johnson EA. Botulinum toxin: the story of its development for the treatment of human disease. Perspect Biol Med 1997; 40: 317–327.

    PubMed  CAS  Google Scholar 

  • Yoshimura DM, Aminoff MJ, Tami TA, Scott AB. Treatment of hemifacial spasm with botulinum toxin. Muscle Nerve 1992; 15: 1045–1049.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Charles H. Adler MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Parkinson’s Disease and Movement, Disorders Center, Department of Neurology, Mayo Clinic Scottsdale, Scottsdale, AZ, USA

    Charles H. Adler MD, PhD (Consultant and Co-Director, Associate Professor of Neurology) (Consultant and Co-Director, Associate Professor of Neurology)

  2. Mayo Medical School, Rochester, MN, USA

    Charles H. Adler MD, PhD (Consultant and Co-Director, Associate Professor of Neurology) & J. Eric Ahlskog PhD, MD (Chair, Consultant, Professor of Neurology) (Consultant and Co-Director, Associate Professor of Neurology) &  (Chair, Consultant, Professor of Neurology)

  3. Division of Movement Disorders, Department of Neurology, Mayo Clinic Rochester, Rochester, MN, USA

    J. Eric Ahlskog PhD, MD (Chair, Consultant, Professor of Neurology) (Chair, Consultant, Professor of Neurology)

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Science+Business Media New York

About this chapter

Cite this chapter

Adler, C.H. (2000). Botulinum Toxin Treatment of Movement Disorders. In: Adler, C.H., Ahlskog, J.E. (eds) Parkinson’s Disease and Movement Disorders. Current Clinical Practice. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-410-8_31

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-410-8_31

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-095-3

  • Online ISBN: 978-1-59259-410-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation